SecBot SecBot
SC TO-I ·Filed Sep 23, 2026

UTMD

UTAH MEDICAL PRODUCTS INC
MIXED
Impact 5/10
Horizonweeks Processed1mo ago SEC0001096906-26-001428
Tender offer (issuer buyback)
Actionable Insight ◆ Mixed

The tender offer provides a near-term catalyst with a fixed $75.00 price and a 6.1% premium to the pre-announcement close. Monitor the tender expiration on October 7 for subscription rate — full subscription would reduce float by ~20% and be accretive to EPS, but the declining revenue trend (down ~14% YoY in H1 2026) tempers the bullish signal. Watch for any extension or price adjustment if market conditions change.

DirectionMixed
Confidencehigh
Horizonweeks
Latest settled — T+20d ⚠ clustered
UTMD ▲ +0.41% at T+20d
NEUTRAL call +0.41% · α vs SPY +0.83% · entry $74.75 → $75.06
Next anchor: T+60d in 7w
Latest observation: T+21 -4.61% FF3 residual α
Entry = T+0 close
Sep 23, 2026
via day close
T+1d
-0.76%
call -0.76% · α -1.31%
$74.18
settled 5w ago
T+5d
-0.54%
call -0.54% · α -0.12%
$74.35
settled 27d ago
T+20d
+0.41%
call +0.41% · α +0.83%
$75.06
settled 6d ago
T+60d
Pending
in 7w

Price Chart

Loading chart...

Executive Summary

UTMD is launching a self-tender offer to repurchase up to 650,000 shares (20.5% of outstanding) at $75.00/share, a 6.1% premium over the $70.67 closing price on September 14, 2026. The offer is funded from cash on hand (estimated $49 million total cost) and is not conditioned on a minimum tender. The Board approved the offer but makes no recommendation; no directors or officers intend to tender. The filing signals management's view that shares are undervalued, but comes amid declining financials: first-half 2026 sales and net profits were 12% and 13% lower year-over-year, respectively.

Key Financial Metrics

Deal Value
$48.8M
Premium
6.1%

Key Facts

  • UTMD offers to buy up to 650,000 shares at $75.00/share, representing ~20.5% of 3,173,818 outstanding shares as of September 14, 2026
  • Offer expires at 5:00 PM ET on October 7, 2026, unless extended
  • Funding from cash on hand; total cost estimated at ~$49 million including expenses
  • No minimum tender condition; odd-lot holders (<100 shares) get priority if oversubscribed
  • No directors or executive officers intend to tender shares in the offer
  • First-half 2026 sales were $8,529,000 vs $9,953,000 in first-half 2025 (down ~14%); net income was $2,686,000 vs $3,048,000 (down ~12%)
  • Pro forma: if fully subscribed, stockholders' equity would drop from ~$122 million to ~$73 million; book value per share from $38.34 to $28.82
  • Closing price on September 14, 2026 was $70.67; offer price is a 6.1% premium to that close

Financial Impact

Aggregate cost of ~$49 million (650,000 shares × $75.00 + ~$250,000 expenses) funded from cash on hand; foregone annual interest income of ~$1.7 million; pro forma EPS accretion from $0.84 to $0.93 for Q2 2026

shares outstandingbook value per sharestockholders' equityEPSinterest income

Risk Factors

  • Revenue and net income declined ~12-14% YoY in first-half 2026, indicating fundamental headwinds
  • Pro forma equity reduction from ~$122M to ~$73M reduces financial flexibility
  • Foregone interest income of ~$1.7M annually reduces other income
  • Offer may not be fully subscribed if shareholders view $75.00 as insufficient premium
  • No minimum tender condition means the company could buy back fewer shares than targeted

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 12 SEC documents filed with EDGAR.

DocumentAccession Number
SC TO-I Filing (Primary)0001096906-26-001428
Document: utmd_exa1b.htm0001096906-26-001428
Document: utmd_sctoi.htm0001096906-26-001428
Document: utmd_exa1e.htm0001096906-26-001428
Document: utmd_exa1d.htm0001096906-26-001428
Document: utmd_ex107.htm0001096906-26-001428
Document: utmd_exa1c.htm0001096906-26-001428
Document: utmd_exa5a.htm0001096906-26-001428
Document: utmd_exa5b.htm0001096906-26-001428
Document: 0001096906-26-001428-index-headers.html0001096906-26-001428
Document: 0001096906-26-001428-index.html0001096906-26-001428
Document: 0001096906-26-001428.txt0001096906-26-001428
8 reports for UTMD
Performance horizon
67% Hit rate @ T+20 2 of 3 directional calls Went positive at some point 2 of 3 best @ T+20▲ +5.45%Apr 23, 2026
Filters
Rows
Reports for UTMD — sortable, filterable
TypeNow
Oct 22, 2026
4d ago
8-K
MIXED ★ 5/10
$75.06awaiting T+20—$73.42 (−2.18%)
Oct 5, 2026
22d ago
SC TO-I/A
NEUTRAL ★ 3/10
$73.31awaiting T+20—$73.42 (+0.15%)
Sep 25, 2026
4w ago
SC TO-C
NEUTRAL ★ 2/10
$74.18 $74.23▲ +0.07%▲ +1.54%$73.42 (−1.02%)
Sep 24, 2026
4w ago
SC TO-C
MIXED ★ 6/10
$74.18 $74.23▲ +0.07%▲ +1.54%$73.42 (−1.02%)
Sep 23, 2026
4w ago
SC TO-I
MIXED ★ 5/10
$74.75 $75.06▲ +0.41%▲ +0.83%$73.42 (−1.78%)
Aug 31, 2026
8w ago
8-K
BULLISH ★ 5/10
$71.13 $74.95▲ +5.37%▲ +5.56%$73.42 (+3.22%)
Jul 23, 2026
13w ago
8-K
BEARISH ★ 7/10
$64.18 $71.42▼ −11.28%▼ −7.97%$73.42 (−14.40%)
Apr 23, 2026
26w ago
8-K
BEARISH ★ 6/10
$67.87 $64.17▲ +5.45%▲ +10.09%$73.42 (−8.18%)
Showing 8 of 8

US Market Status

Market Open — Closes in 3h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 23, 2026